133 related articles for article (PubMed ID: 38797048)
1. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study.
Solignac M; Cabrera N; Fouillet-Desjonqueres M; Duquesne A; Laurent A; Foray AP; Viel S; Zekre F; Belot A
J Autoimmun; 2024 May; 147():103248. PubMed ID: 38797048
[TBL] [Abstract][Full Text] [Related]
2. JAK inhibitors in systemic juvenile idiopathic arthritis.
He T; Xia Y; Luo Y; Yang J
Front Pediatr; 2023; 11():1134312. PubMed ID: 37152309
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
[TBL] [Abstract][Full Text] [Related]
4. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
Gillard L; Pouchot J; Cohen-Aubart F; Koné-Paut I; Mouterde G; Michaud M; Reumaux H; Savey L; Belot A; Fautrel B; Mitrovic S
Rheumatology (Oxford); 2023 Apr; 62(4):1594-1604. PubMed ID: 35920788
[TBL] [Abstract][Full Text] [Related]
5. JAK inhibitors in the treatment of adult patients with juvenile idiopathic arthritis: a retrospective monocentric experience.
Chighizola CB; Pellico MR; Pandolfi M; Marelli L; Cornalba M; Pontikaki I; Costi S; Gattinara M; Marino A; Miserocchi E; Caporali R
Clin Exp Rheumatol; 2024 May; 42(5):974-982. PubMed ID: 38530666
[TBL] [Abstract][Full Text] [Related]
6. The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience.
Kostik MM; Raupov RK; Suspitsin EN; Isupova EA; Gaidar EV; Gabrusskaya TV; Kaneva MA; Snegireva LS; Likhacheva TS; Miulkidzhan RS; Kosmin AV; Tumakova AV; Masalova VV; Dubko MF; Kalashnikova OV; Aksentijevich I; Chasnyk VG
Front Pediatr; 2022; 10():820586. PubMed ID: 35211430
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study.
Fischer M; Olbrich P; Hadjadj J; Aumann V; Bakhtiar S; Barlogis V; von Bismarck P; Bloomfield M; Booth C; Buddingh EP; Cagdas D; Castelle M; Chan AY; Chandrakasan S; Chetty K; Cougoul P; Crickx E; Dara J; Deyà-Martínez A; Farmand S; Formankova R; Gennery AR; Gonzalez-Granado LI; Hagin D; Hanitsch LG; Hanzlikovà J; Hauck F; Ivorra-Cortés J; Kisand K; Kiykim A; Körholz J; Leahy TR; van Montfrans J; Nademi Z; Nelken B; Parikh S; Plado S; Ramakers J; Redlich A; Rieux-Laucat F; Rivière JG; Rodina Y; Júnior PR; Salou S; Schuetz C; Shcherbina A; Slatter MA; Touzot F; Unal E; Lankester AC; Burns S; Seppänen MRJ; Neth O; Albert MH; Ehl S; Neven B; Speckmann C
J Allergy Clin Immunol; 2024 Jan; 153(1):275-286.e18. PubMed ID: 37935260
[TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study.
Tsujii A; Isoda K; Yoshimura M; Nakabayashi A; Kim DS; Tamada T; Yamamoto K; Ohshima S
BMC Rheumatol; 2024 Jan; 8(1):4. PubMed ID: 38273359
[TBL] [Abstract][Full Text] [Related]
9. Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.
Golhen K; Winskill C; Yeh C; Zhang N; Welzel T; Pfister M
Front Pediatr; 2022; 10():909118. PubMed ID: 35799700
[TBL] [Abstract][Full Text] [Related]
10. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review.
Boyadzhieva Z; Ruffer N; Burmester G; Pankow A; Krusche M
Front Med (Lausanne); 2022; 9():930071. PubMed ID: 35833101
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.
Eriksson P; Skoglund O; Hemgren C; Sjöwall C
Front Immunol; 2023; 14():1187584. PubMed ID: 37304255
[TBL] [Abstract][Full Text] [Related]
13. Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study.
Yoshida S; Miyata M; Suzuki E; Kanno T; Sumichika Y; Saito K; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Asano T; Sato S; Migita K
Front Immunol; 2023; 14():1267749. PubMed ID: 37868999
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology.
Ll Wilkinson MG; Deakin CT; Papadopoulou C; Eleftheriou D; Wedderburn LR
Pediatr Rheumatol Online J; 2021 Sep; 19(1):146. PubMed ID: 34563217
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update.
Chuprin J; McCormack L; Richmond JM; Rashighi M
Expert Rev Clin Immunol; 2022 Mar; 18(3):263-272. PubMed ID: 35209781
[TBL] [Abstract][Full Text] [Related]
16. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma.
Tachet J; Versace F; Mercier T; Buclin T; Decosterd LA; Choong E; Girardin FR
J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123917. PubMed ID: 37956468
[TBL] [Abstract][Full Text] [Related]
18. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.
Zhang J; Sun L; Shi X; Li S; Liu C; Li X; Lu M; Deng J; Tan X; Guan W; Li G; Wen X; Liu P; Li C
Arthritis Res Ther; 2023 Oct; 25(1):204. PubMed ID: 37853451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
